Silence Therapeutics (SLN) Gains from Investment Securities (2021 - 2026)
Silence Therapeutics recorded quarterly Gains from Investment Securities of -$88000.0 in Q1 2026, down 101.18% quarter-over-quarter from $7.4 million in Q4 2025, and down 15.79% year-over-year from -$104500.0 in Q1 2025.
Silence Therapeutics' Gains from Investment Securities history runs 6 years deep, the most recent figure standing at -$88000.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities fell 15.79% year-over-year to -$88000.0; the TTM figure through Mar 2026 stood at $14.4 million (up 110.61% YoY), while the FY2025 annual figure was $7.0 million, down 60.12% from the prior year.
- Gains from Investment Securities came in at -$88000.0 for Q1 2026 at Silence Therapeutics, down from $7.4 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $13.6 million in Q4 2022 to a low of -$109141.2 in Q3 2024.
- A 5-year average of $3.8 million and a median of $423551.0 in 2025 frame the typical range for Gains from Investment Securities.
- On a YoY basis, Gains from Investment Securities climbed as much as 6648.54% in 2025 and fell as far as 300.0% in 2025.
- Silence Therapeutics' Gains from Investment Securities stood at $13.6 million in 2022, then plunged by 51.68% to $6.6 million in 2023, then grew by 8.65% to $7.1 million in 2024, then increased by 4.27% to $7.4 million in 2025, then sank by 101.18% to -$88000.0 in 2026.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered -$88000.0, $7.4 million, and $423551.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Silence Therapeutics | 924.61 Mn | 854.53 Mn | 411,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -88,000.00 |
| Mar 31, 2026 | -88,000.00 |
| Dec 31, 2025 | 7.43 Mn |
| Dec 31, 2025 | 7.43 Mn |
| Sep 30, 2025 | 423,551.00 |
| Sep 30, 2025 | 423,551.00 |
| Jun 30, 2025 | 7.03 Mn |
| Jun 30, 2025 | 7.03 Mn |
| Mar 31, 2025 | -76,000.00 |
| Mar 31, 2025 | -76,000.00 |
| Dec 31, 2024 | 7.13 Mn |
| Dec 31, 2024 | 7.13 Mn |
| Sep 30, 2024 | -109,141.21 |
| Sep 30, 2024 | -109,141.21 |
| Jun 30, 2024 | -107,288.76 |
| Jun 30, 2024 | -107,288.76 |
| Mar 31, 2024 | -19,000.00 |
| Mar 31, 2024 | -19,000.00 |
| Dec 31, 2023 | 6.56 Mn |
| Dec 31, 2023 | 6.56 Mn |
| Dec 31, 2022 | 13.57 Mn |
| Dec 31, 2022 | 13.57 Mn |
| Dec 31, 2021 | 3.62 Mn |
| Dec 31, 2021 | 3.62 Mn |